-
Mashup Score: 0STOP-CA Clinical Trial Finds Statins Lower Rate of Heart Decline in Lymphoma Patients, Late-Breaking ACC23 Clinical Trial Reports - 1 year(s) ago
March 4, 2023 — The impact of statin use to prevent heart damage during a cancer patient’s chemotherapy was in focus during a late-breaking scientific session, on the STOP-CA Trial, presented at the American College of Cardiology’s Annual Scientific Session Together with the World Congress of Cardiology, ACC.23/WCC, being held March 4-6 in New Orleans, LA. In “Statins to Prevent the…
Source: DAICCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 16Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines: - 2 year(s) ago
Abstract Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among patients with established heart failure. Despite supportive basic science studies, there are no data on…
Source: JACC: Heart FailureCategories: Expert Picks, Latest HeadlinesTweet-
New issue of #JACCHF is out! #SGLT2 inhibitors associated w/ fewer #HeartFailure admissions. New cardiomyopathy and arrhythmias among patients w/ #cancer and #diabetes mellitus treated w/ #anthracyclines, according to new retrospective report. https://t.co/u77XIcecqu #CardioOnc https://t.co/rENfoZIESJ
-
-
Mashup Score: 10Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines: - 2 year(s) ago
Abstract Background Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve outcomes among patients with established heart failure. Despite supportive basic science studies, there are no data on…
Source: JACC: Heart FailureCategories: Cardiologists, Latest HeadlinesTweet-
SGLT2i and Cardiac Outcomes Among Patients Treated With Anthracyclines This retrospective cohort study showed that the use of #SGLT2i in DM pts being treated with #anthracyclines is safe and associated with a lower cardiac event rate https://t.co/HB30blpv1X #JACCHF @JACCJournals https://t.co/NxCWjACwxV
-
-
Mashup Score: 6
Edited by Associate Editor Laurie Sehn, this How I Treat series features 5 state-of-the-art advisory pieces on how experts tackle recurring medical problems tha
Source: American Society of HematologyCategories: Cardiologists, Latest HeadlinesTweet-
How I treat CV complications in patients with #lymphoid malignancies #Cardiomyopathy, #HeartFailure,and arrhythmias remain of greatest concerns with the use of #anthracyclines, hematopoietic stem cell transplantation, and radiation therapy https://t.co/IUiTjJvyac #CardioOncology https://t.co/E8rA2Hsb5O
-
-
Mashup Score: 2
AbstractAims. Trastuzumab and anthracyclines, often used in the treatment of breast cancer, may impair myocardial function, and reduce left ventricular ejection
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 6Chemotherapy With or Without Anthracyclines in Patients With ERBB2-Positive Breast Cancer - 3 year(s) ago
This randomized clinical trial evaluates 3-year event-free survival and overall survival of an anthracycline-free and anthracycline-containing regimen with dual ERBB2 blockade in patients with stage II and III ERBB2-positive breast cancer.
Source: jamanetwork.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Meeting Library | Meeting Library - 4 year(s) ago
2318 Mill Road, Suite 800, Alexandria, VA 22314 · 571-483-1300 ©2020 American Society of Clinical Oncology (ASCO). All Rights Reserved Worldwide.
Source: meetinglibrary.asco.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
@DAICeditor In the #STOP_CA Trial researchers found that among people receiving chemotherapy regimens containing #anthracyclines for #lymphoma, those who took #atorvastatin for one year were significantly less likely to show evidence of #heartdysfunction: https://t.co/Y515xvA4nT